NCT03706326Unknown1 期
Combination Therapy of Anti-MUC1 CAR T Cells and PD-1 Knockout Engineered T Cells for Advanced Esophageal Cancer
The First Affiliated Hospital of Guangdong Pharmaceutical University2 个研究点 分布在 1 个国家目标入组 20 人开始时间: 2018年9月28日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 发起方
- 入组人数
- 20
- 试验地点
- 2
- 主要终点
- Number of participants with adverse events and dose limiting toxicities as assessed by CTCAE v4.0
研究概览
简要总结
The study is to assess the safety and efficacy of the immunotherapies using anti-MUC1 CAR T cells and /or PD-1 knockout engineered T cells in the treatment of patients with advanced esophageal cancer.
详细描述
This is a combined phase 1 and 2 clinical study. The aim of the study is to assess the safety and efficacy of the immunotherapies using anti- MUC1 CAR T cells alone, anti- MUC1 CAR T combining PD-1 knockout engineered T cells, and PD-1 knockout engineered T cell only in the treatment of patients with advanced esophageal cancer. The treatment outcomes from each group will be compared.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Participant)
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Confirmed diagnosis of advanced esophageal cancer (phase IIIb-IV) according to NCCN clinical practice guidelines in Oncology:Esophageal and Esophagogastric Junction Cancers (2018.V1).
- •MUC1 is highly expressed in malignancy tissues by immuno-histochemical (IHC).
- •Eastern cooperative oncology group (ECOG) performance status of 0-1 or karnofsky performance status (KPS) score is higher than
- •Patients have a life expectancy > 12 weeks.
- •Adequate venous access for apheresis or venous sampling, and no other contraindications for leukapheresis.
- •Negative pregnancy test for females of child-bearing potentials.
- •Adequate bone marrow, liver and renal function as assessed by the following laboratory requirements: White blood cell count (WBC) ≥ 2500c/ml, Platelets ≥ 50×10^9/L, Hb ≥ 9.0g/dL, lymphocyte (LY) ≥ 0.7×10^9/L, LY% ≥ 15%, Alb ≥ 2.8g/dL, serum lipase and amylase < 1.5×upper limit of normal, serum creatinine ≤ 2.5mg/dL, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 5×upper limit of normal, serum total bilirubin ≤ 2.0mg/dL. These tests must be conducted within 7 days prior to registration.
- •Signed informed consent form.
排除标准
- •Number of T cells is less than 10% or the amplification of the T cells via artificial antigen presenting cell (aAPC) stimulation is less than 5 times.
- •Patients with symptomatic central nervous system (CNS) involvement.
- •Pregnant or nursing women.
- •Known HIV, HBV and HCV infection.
- •Serious illness or medical condition which would not permit the patient to be managed according to the protocol, including active uncontrolled infection, major cardiovascular, coagulation disorders, respiratory or immune system, myocardial infarction, cardiac arrhythmias, obstructive/restrictive pulmonary disease, or psychiatric or emotional disorders.
- •History of severe immediate hypersensitivity to any of the agents including cyclophosphamide, fludarabine, or aldesleukin.
- •Concurrent use of systemic steroids. Recent or current use of inhaled steroids is not exclusionary.
- •Previously treatment with any gene therapy products.
- •The existence of unstable or active ulcers or gastrointestinal bleeding. Patients with portal vein vascular invasion or extrahepatic, are excluded from this study.
- •Patients with a history of organ transplantation or are waiting for organ transplantation.
结局指标
主要结局
Number of participants with adverse events and dose limiting toxicities as assessed by CTCAE v4.0
时间窗: approximately 12 months
Safety and tolerability of dose of CART-cells and PD-1 Knockout T cells will be assessed using CTCAE v4.0.
次要结局
- Progression free survival - PFS(Up to 12 months)
- Response Rate(12 months)
- Overall Survival - OS(Up to 24 months)
- Median CAR-T cell persistence(3 years)
研究者
Size Chen
Associate Professor
The First Affiliated Hospital of Guangdong Pharmaceutical University
研究点 (2)
Loading locations...
相似试验
Unknown
1 期
Anti-MUC1 CAR T Cells and PD-1 Knockout Engineered T Cells for NSCLCLung Neoplasm MalignantNon-small Cell Lung CancerNCT03525782The First Affiliated Hospital of Guangdong Pharmaceutical University60
Unknown
1 期
Phase I/II Study of Anti-Mucin1 (MUC1) CAR T Cells for Patients With MUC1+ Advanced Refractory Solid TumorPancreatic CarcinomaTriple-Negative Invasive Breast CarcinomaHepatocellular CarcinomaNon-small Cell Lung CancerNCT02587689PersonGen BioTherapeutics (Suzhou) Co., Ltd.20
招募中
1 期
MUC1-Activated T Cells for the Treatment of Relapsed and Resistant Ovarian CancerPlatinum-Resistant Fallopian Tube CarcinomaPlatinum-Resistant Ovarian CarcinomaPlatinum-Resistant Primary Peritoneal CarcinomaRecurrent Fallopian Tube CarcinomaRecurrent Fallopian Tube CarcinosarcomaRecurrent Female Reproductive System CarcinomaRecurrent Ovarian CarcinomaRecurrent Ovarian CarcinosarcomaRecurrent Platinum-Resistant Fallopian Tube CarcinomaRecurrent Platinum-Resistant Ovarian CarcinomaRecurrent Primary Peritoneal CarcinomaRecurrent Primary Peritoneal CarcinosarcomaRefractory Fallopian Tube CarcinomaRefractory Female Reproductive System CarcinomaRefractory Ovarian CarcinomaRefractory Primary Peritoneal CarcinomaNCT06483048Mayo Clinic12
Unknown
1 期
CAR-T Cell Immunotherapy in MUC1 Positive Solid TumorMalignant Glioma of BrainColorectal CarcinomaGastric CarcinomaNCT02617134PersonGen BioTherapeutics (Suzhou) Co., Ltd.20
撤回
1 期
CAR-T Cell Immunotherapy for HCC Targeting GPC3GPC3 Positive Hepatocellular CarcinomaCAR-T Cell ImmunotherapyNCT02723942Fuda Cancer Hospital, Guangzhou